DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Slamon DJ, Fasching PA, Patel R. et al.
NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).
J Clin Oncol 2019;
37: TPS597-TPS597
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.